NCT02254447View on ClinicalTrials.gov

Relative Bioavailability Study of Candesartan Cilexetil Under Fasting Conditions

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

December 2, 2014

Primary Completion Date

January 8, 2015

Study Completion Date

January 8, 2015

Conditions
Cardiovascular Disease
Interventions
DRUG

Candesartan Cilexetil in formulation 1

Round, biconvex white tablets containing Candesartan cilexetil 16 mg for oral administration

DRUG

Candesartan Cilexetil in formulation 2

Round, biconvex white tablets containing Candesartan cilexetil 16 mg for oral administration

DRUG

ATACAND

Round, biconvex pink tablets containing Candesartan cilexetil 16 mg for oral administration

Trial Locations (1)

500 013

GSK Investigational Site, Hyderabad

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT02254447 - Relative Bioavailability Study of Candesartan Cilexetil Under Fasting Conditions | Biotech Hunter | Biotech Hunter